Physician profile
Steven Marvel
NPI 1588771323
$7,622.04
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $1,842 · 2021: $2,407 · 2022: $1,386 · 2024: $21.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,383.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,229.09 | 2019-2022 | |
| United Therapeutics Corporation | $741.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.25 | 2019-2022 | |
| Grifols USA, LLC | $522.23 | 2019-2022 | |
| Genentech USA, INC. | $447.77 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $357.46 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.67 | 2020-2022 | |
| Mylan Specialty L.P. | $195.21 | 2019-2022 | |
| Insmed, INC. | $194.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.03 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $172.42 | 2019-2022 | |
| Electromed, INC. | $161.80 | 2021 | |
| Genzyme Corporation | $156.17 | 2019-2022 | |
| Philips North America LLC | $155.42 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $151.05 | 2019-2022 | |
| Amgen INC. | $146.78 | 2021-2022 | |
| Gilead Sciences, INC. | $134.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.58 | 2019-2021 | |
| Shire North American Group INC | $91.29 | 2019 | |
| Abbvie INC. | $70.91 | 2021 | |
| Pfizer INC. | $62.88 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $52.25 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $37.04 | 2019 | |
| Allergan, INC. | $35.05 | 2019-2020 | |
| Harmony Biosciences LLC | $34.59 | 2021 | |
| Circassia INC. | $27.35 | 2019 | |
| Abiomed | $15.85 | 2019 | |
| Eusa Pharma (US) LLC | $11.11 | 2020 | |
| Advanced Respiratory, INC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Marvel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.